APCEDENÂ , Dendritic cell based Immunotherapy for the treatment of cancer.

ABSTRACT: Primary outcome(s): 1. Overall Survival 2. Evaluation of objective response through Immune related Response Criteria (irRC): measure of PD; PR and SD. 3. Immune response as assessed through Treg population and serum IFN-γ levels 4. Monitor treatment emergent adverse events. Timepoint: 1. Overall Survival 2. Evaluation of objective response through Immune related Response Criteria (irRC): measure of PD; PR and SD. 3. Immune response as assessed through Treg population and serum IFN-γ levels 4. Monitor treatment emergent adverse events.

DISEASE(S): Patients With A Histologically Confirmed Diagnosis Of Ovarian Cancer, Prostate Cancer,metastatic Adenocarcinoma Of The Lung And Colorectal Carcinoma.age: 18 To 75 Years

PROVIDER: 2581299 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR